Compare Cassava Sciences Inc (FLNA) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Symbotic Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Symbotic Inc trades at $42.3 (market cap $5.62B). The key difference: Symbotic Inc is far larger — about 142.6× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 1,339,679). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Symbotic Inc for 23 Days on average.
| FLNA | SYM | |
|---|---|---|
Market Cap | $39.40M | $5.62B |
Volume | 759,018 | 1,339,679 |
Sector | Health | Industrials |
52-Week High | $4.64 | $87.30 |
52-Week Low | $0.68 | $38.22 |
Typical Hold Time | 37 Days | 23 Days |
Enterprise Value | -$43.28M | $3.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
SYM trades at $43.31, down 1.9% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth potential with a $22.5 billion backlog but faces profitability challenges with negative net income of -$16.94 million in 2025. Analyst consensus is positive with a $60.33 price target, though recent earnings misses and customer concentration risk remain concerns.
SYM presents a growth opportunity in warehouse automation with significant backlog and expanding market demand, but investors must weigh high valuation multiples against current profitability issues and execution risks. The stock's upside depends on successful margin expansion and diversification beyond its major customer relationship.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
